Taiflex Scientific Co., Ltd.
TWSE:8039.TW
50.3 (TWD) • At close November 8, 2024
Overview | Financials
Numbers are in millions (except for per share data and ratios) TWD.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 8,150.519 | 8,721.875 | 9,405.002 | 8,766.318 | 7,583.654 | 9,643.051 | 11,192.892 | 10,283.979 | 10,267.868 | 10,127.72 | 10,138.227 | 7,853.228 | 6,485.299 | 6,859.536 | 3,909.099 |
| Cost of Revenue
| 6,359.012 | 6,643.012 | 7,206.359 | 6,687.745 | 5,844.516 | 7,650.007 | 9,058.315 | 8,388.233 | 8,103.053 | 7,871.171 | 7,968.677 | 6,290.054 | 5,091.913 | 5,194.033 | 3,026.225 |
| Gross Profit
| 1,791.507 | 2,078.863 | 2,198.643 | 2,078.573 | 1,739.138 | 1,993.044 | 2,134.577 | 1,895.746 | 2,164.815 | 2,256.549 | 2,169.55 | 1,563.174 | 1,393.386 | 1,665.503 | 882.874 |
| Gross Profit Ratio
| 0.22 | 0.238 | 0.234 | 0.237 | 0.229 | 0.207 | 0.191 | 0.184 | 0.211 | 0.223 | 0.214 | 0.199 | 0.215 | 0.243 | 0.226 |
| Reseach & Development Expenses
| 366.518 | 400.591 | 323.22 | 281.36 | 284.486 | 264.278 | 257.468 | 217.559 | 218.559 | 189.228 | 158.711 | 135.036 | 86.846 | 82.407 | 60.74 |
| General & Administrative Expenses
| 478.979 | 486.493 | 424.366 | 344.566 | 361.941 | 450.461 | 414.505 | 340.322 | 399.605 | 399.638 | 432.409 | 345.618 | 357.745 | 332.268 | 190.354 |
| Selling & Marketing Expenses
| 455.45 | 537.631 | 506.635 | 417.547 | 374.759 | 445.484 | 473.619 | 383.184 | 497.436 | 657.652 | 465.855 | 300.175 | 261.15 | 220.508 | 150.958 |
| SG&A
| 934.429 | 1,024.124 | 931.001 | 762.113 | 736.7 | 895.945 | 888.124 | 723.506 | 897.041 | 1,057.29 | 898.264 | 645.793 | 618.895 | 552.776 | 341.312 |
| Other Expenses
| 10.771 | 250.768 | 15.4 | -48.055 | 88.971 | -70.5 | 36.393 | -178.739 | -107.178 | 173.024 | 208.952 | 10.949 | 27.598 | 13.177 | 21.092 |
| Operating Expenses
| 1,300.947 | 1,424.715 | 1,254.221 | 1,043.473 | 1,021.186 | 1,160.223 | 1,145.687 | 941.16 | 1,115.695 | 1,246.631 | 1,057.092 | 780.829 | 705.741 | 635.183 | 402.052 |
| Operating Income
| 517.737 | 918.587 | 957.226 | 978.775 | 789.335 | 832.821 | 988.89 | 954.586 | 1,049.12 | 1,009.918 | 1,112.458 | 782.345 | 687.645 | 1,030.32 | 480.822 |
| Operating Income Ratio
| 0.064 | 0.105 | 0.102 | 0.112 | 0.104 | 0.086 | 0.088 | 0.093 | 0.102 | 0.1 | 0.11 | 0.1 | 0.106 | 0.15 | 0.123 |
| Total Other Income Expenses Net
| -35.418 | -41.274 | -16.412 | -12.978 | 3.119 | 35.721 | -29.792 | -271.188 | -181.85 | 97.265 | 166.219 | -44.127 | 87.511 | -17.606 | -23.169 |
| Income Before Tax
| 482.319 | 877.313 | 940.814 | 965.797 | 792.454 | 868.542 | 959.098 | 683.398 | 867.27 | 1,107.183 | 1,278.677 | 738.218 | 775.156 | 1,012.714 | 457.653 |
| Income Before Tax Ratio
| 0.059 | 0.101 | 0.1 | 0.11 | 0.104 | 0.09 | 0.086 | 0.066 | 0.084 | 0.109 | 0.126 | 0.094 | 0.12 | 0.148 | 0.117 |
| Income Tax Expense
| 121.596 | 185.6 | 195.952 | 181.444 | 174.172 | 189.068 | 212.553 | 136.788 | 159.962 | 222.204 | 253.231 | 133.767 | 221.183 | 229.705 | 93.403 |
| Net Income
| 422.974 | 700.483 | 734.654 | 772.859 | 630.681 | 672.309 | 734.589 | 579.678 | 729.856 | 882.421 | 1,005.346 | 620.067 | 562.985 | 779.89 | 364.25 |
| Net Income Ratio
| 0.052 | 0.08 | 0.078 | 0.088 | 0.083 | 0.07 | 0.066 | 0.056 | 0.071 | 0.087 | 0.099 | 0.079 | 0.087 | 0.114 | 0.093 |
| EPS
| 2.02 | 3.35 | 3.51 | 3.7 | 3.02 | 3.22 | 3.55 | 2.81 | 3.54 | 4.24 | 4.86 | 3.02 | 2.75 | 3.97 | 1.9 |
| EPS Diluted
| 1.73 | 2.87 | 2.98 | 3.67 | 3 | 3.18 | 3.53 | 2.79 | 3.51 | 4.2 | 4.79 | 2.93 | 2.65 | 3.79 | 1.89 |
| EBITDA
| 976.942 | 1,350.487 | 1,354.154 | 1,313.364 | 1,139.111 | 1,102.264 | 1,326.859 | 1,078.287 | 1,240.727 | 1,456.588 | 1,578.038 | 1,021.502 | 1,108.965 | 1,288.278 | 683.244 |
| EBITDA Ratio
| 0.12 | 0.155 | 0.144 | 0.15 | 0.15 | 0.114 | 0.119 | 0.105 | 0.121 | 0.144 | 0.156 | 0.13 | 0.171 | 0.188 | 0.175 |